Autopolymerisable Prosthetic Base Material Residual MMA Reduction

The patent changes the chemical composition parameters by introducing N-alkyl-substituted acryloyloxy carbamate and di-functional urethane (meth)acrylate monomers with specific molecular masses (≤250 g/mol) to replace part of the traditional MMA monomer system. This parameter change enables cold-curing materials to achieve residual MMA content ≤2.2% by weight while maintaining ease of processing, thus resolving the contradiction between ease of operation and harmful residual monomer content.

The patent creates a composite material system combining multiple monomer types (methylmethacrylate, N-alkyl-substituted acryloyloxy carbamate, di-functional urethane (meth)acrylate) with specific molecular mass characteristics. This composite approach achieves transparency ≥90% while maintaining fracture toughness ≥2 MPa·m¹/², resolving the contradiction between transparency and strength by synergistically combining different monomer properties.

The patent implements parameter changes by specifying precise molecular mass limits (≤250 g/mol) for the N-alkyl-substituted acryloyloxy carbamate and di-functional urethane (meth)acrylate monomers. This parameter control enables the material to achieve fracture toughness ≥2 MPa·m¹/² while keeping residual MMA content ≤2.2% by weight, simultaneously satisfying both strength and safety requirements.

The patent applies local quality by incorporating polymeric particles with at least three different size fractions into the prosthetic base material. This creates a hierarchical structure where different particle sizes fulfill different functions: smaller particles fill gaps for homogeneity, medium particles provide structural framework, and larger particles contribute to mechanical strength. The mixture is processed using standard dental technology without requiring elaborate additional devices, thus achieving manufacturing precision while avoiding excessive device complexity.